Improving Effective Basal Insulin Use in Clinical Practice
ADA Guideline Recommendations for Basal Insulin Use in T2D
Barriers to Insulin Use: Clinician-Level Factors
Barriers to Insulin Use: System-Level Factors
Barriers to Insulin Use: Patient-Level Factors
Communication Between Clinicians and Patients
Generics vs Biosimilars/Biologics
Follow-On Basal Insulin Therapy
Comparison of Follow-On Insulin With Traditional Insulin
Place of Follow-On Basal Insulin in Clinical Practice
Patient Opinion on Use of Biosimilar Insulin
Continued Role of NPH Insulin
Patient Communication: Switching From U100 Glargine to Follow-On Insulin Glargine U100
Experience With Biosimilar Glargine in Europe
Role of Basal Insulin in Type 2 Diabetes
Follow-On Basal Insulin Glargine in Insulin-Naive Patients
Follow-On Basal Insulin: Cost
Key Takeaways
Abbreviations